Iovance Biotherapeutics
Open
$4.06
Prev. Close
$4.06
High
$4.10
Low
$4.06
Market Snapshot
$1.68B
-4.7
-1.29
$164.07M
975
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The firm is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
Iovance Biotherapeutics received conditional approval for Amtagvi in Australia and FDA clearance for IOV-5001 trials, significantly advancing its therapy development.
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 975 full-time employees. The company went IPO on 2008-06-20. The firm is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. The company is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
Recently from Cashu
Overcoming Manufacturing Challenges in Cell Therapy: Insights from Iovance Biotherapeutics
A New Era for Cell Therapy: Overcoming Manufacturing Challenges Iovance Biotherapeutics stands at the forefront of an evolving landscape in the cell therapy sector, a domain that is gaining momentum d…
Iovance Biotherapeutics: Pioneering Cell-Based Therapies in Regenerative Medicine and Cancer Treatment
Iovance Biotherapeutics and the Transformative Potential of Cell-Based Therapies Iovance Biotherapeutics operates at the cutting edge of regenerative medicine, focusing on the development of advanced…
Iovance Biotherapeutics: Leading Trends in Personalized Cell Therapy for Cancer Treatment
Emerging Trends in Cell Therapy: Iovance Biotherapeutics Leads the Way Iovance Biotherapeutics Inc., a prominent player in the cell therapy landscape, continues to pave the way for innovative cancer t…
Iovance Biotherapeutics Examines Rising Competition in Colorectal Cancer Treatment Innovations
Iovance Biotherapeutics Faces Growing Competition in Colorectal Cancer Innovations As Iovance Biotherapeutics navigates the complex landscape of cancer therapies, it encounters significant development…